| . | Total cholesterol, mmol/L . | LDL cholesterol, mmol/L . | Triglycerides, mmol/L . | HDL cholesterol, mmol/L . |
|---|---|---|---|---|
| Age, y | 0.12 (0.02 to 0.22) P = .0160 | 0.13 (−0.02 to 0.28) P = .08 | 0.19 (−0.06 to 0.44) P = .14 | −0.08 (−0.21 to 0.06) P = .24 |
| BMI | 0.19 (0.05 to 0.0.32) P = .0063 | 0.63 (0.44 to 0.83) P ≤ .0001 | 0.80 (0.47 to 1.13) P ≤ .0001 | −0.59 (−0.77 to −0.41) P ≤ .0001 |
| Karyotype, 45, X or other | 3.3% (−3.5% to 10.6%) P = .34 | 2.8% (−7.1% to 13.7%) P = .59 | 8.8% (−8.5% to 29.4%) P = .33 | 4.1% (−6.9% to 16.4%) P = .47 |
| ERT, Y/N | 0.4% (−6.0% to 7.2%) P = .90 | −1.6% (−10.5% to 8.2%) P = .74 | 2.4% (−13.1% to 20.7%) P = .77 | 0.6% (−7.4% to 9.3%) P = .88 |
| Statin, Y/N | −12.0% (−18.2% to −5.3%) P = .0007 | −24.9% (−32.3% to −16.6%) P ≤ .0001 | −4.3% (−20.2% to 14.8%) P = .63 | 5.0% (−4.0% to 14.8%) P = .28 |
| Antidiabetic medication, Y/N | −13.3% (−19.5% to −6.6%) P = .0002 | −19.2% (−27.3% to −10.2%) P ≤ .0001 | −0.8% (−16.1% to 21.2%) P = .92 | −5.7% (−13.9% to 3.4%) P = .21 |
| . | Total cholesterol, mmol/L . | LDL cholesterol, mmol/L . | Triglycerides, mmol/L . | HDL cholesterol, mmol/L . |
|---|---|---|---|---|
| Age, y | 0.12 (0.02 to 0.22) P = .0160 | 0.13 (−0.02 to 0.28) P = .08 | 0.19 (−0.06 to 0.44) P = .14 | −0.08 (−0.21 to 0.06) P = .24 |
| BMI | 0.19 (0.05 to 0.0.32) P = .0063 | 0.63 (0.44 to 0.83) P ≤ .0001 | 0.80 (0.47 to 1.13) P ≤ .0001 | −0.59 (−0.77 to −0.41) P ≤ .0001 |
| Karyotype, 45, X or other | 3.3% (−3.5% to 10.6%) P = .34 | 2.8% (−7.1% to 13.7%) P = .59 | 8.8% (−8.5% to 29.4%) P = .33 | 4.1% (−6.9% to 16.4%) P = .47 |
| ERT, Y/N | 0.4% (−6.0% to 7.2%) P = .90 | −1.6% (−10.5% to 8.2%) P = .74 | 2.4% (−13.1% to 20.7%) P = .77 | 0.6% (−7.4% to 9.3%) P = .88 |
| Statin, Y/N | −12.0% (−18.2% to −5.3%) P = .0007 | −24.9% (−32.3% to −16.6%) P ≤ .0001 | −4.3% (−20.2% to 14.8%) P = .63 | 5.0% (−4.0% to 14.8%) P = .28 |
| Antidiabetic medication, Y/N | −13.3% (−19.5% to −6.6%) P = .0002 | −19.2% (−27.3% to −10.2%) P ≤ .0001 | −0.8% (−16.1% to 21.2%) P = .92 | −5.7% (−13.9% to 3.4%) P = .21 |
Coefficients for repeated-measurement analysis on visit 1 to 4. Estimates are followed by 95% CI in parentheses and P values. P values less than .05 appear in bold. Age and BMI are exponential, for example, ageb while karyotype, ERT, statin, and antidiabetic medication are in percentage changes. For karyotype 45, X is reference to non-45, X. For ERT, statin, and antidiabetic medication, no treatment is reference to treatment, that is, the estimates are the effect of the specific treatment.
Abbreviations: BMI, body mass index; ERT, estrogen replacement therapy; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N, no; Y, yes.
| . | Total cholesterol, mmol/L . | LDL cholesterol, mmol/L . | Triglycerides, mmol/L . | HDL cholesterol, mmol/L . |
|---|---|---|---|---|
| Age, y | 0.12 (0.02 to 0.22) P = .0160 | 0.13 (−0.02 to 0.28) P = .08 | 0.19 (−0.06 to 0.44) P = .14 | −0.08 (−0.21 to 0.06) P = .24 |
| BMI | 0.19 (0.05 to 0.0.32) P = .0063 | 0.63 (0.44 to 0.83) P ≤ .0001 | 0.80 (0.47 to 1.13) P ≤ .0001 | −0.59 (−0.77 to −0.41) P ≤ .0001 |
| Karyotype, 45, X or other | 3.3% (−3.5% to 10.6%) P = .34 | 2.8% (−7.1% to 13.7%) P = .59 | 8.8% (−8.5% to 29.4%) P = .33 | 4.1% (−6.9% to 16.4%) P = .47 |
| ERT, Y/N | 0.4% (−6.0% to 7.2%) P = .90 | −1.6% (−10.5% to 8.2%) P = .74 | 2.4% (−13.1% to 20.7%) P = .77 | 0.6% (−7.4% to 9.3%) P = .88 |
| Statin, Y/N | −12.0% (−18.2% to −5.3%) P = .0007 | −24.9% (−32.3% to −16.6%) P ≤ .0001 | −4.3% (−20.2% to 14.8%) P = .63 | 5.0% (−4.0% to 14.8%) P = .28 |
| Antidiabetic medication, Y/N | −13.3% (−19.5% to −6.6%) P = .0002 | −19.2% (−27.3% to −10.2%) P ≤ .0001 | −0.8% (−16.1% to 21.2%) P = .92 | −5.7% (−13.9% to 3.4%) P = .21 |
| . | Total cholesterol, mmol/L . | LDL cholesterol, mmol/L . | Triglycerides, mmol/L . | HDL cholesterol, mmol/L . |
|---|---|---|---|---|
| Age, y | 0.12 (0.02 to 0.22) P = .0160 | 0.13 (−0.02 to 0.28) P = .08 | 0.19 (−0.06 to 0.44) P = .14 | −0.08 (−0.21 to 0.06) P = .24 |
| BMI | 0.19 (0.05 to 0.0.32) P = .0063 | 0.63 (0.44 to 0.83) P ≤ .0001 | 0.80 (0.47 to 1.13) P ≤ .0001 | −0.59 (−0.77 to −0.41) P ≤ .0001 |
| Karyotype, 45, X or other | 3.3% (−3.5% to 10.6%) P = .34 | 2.8% (−7.1% to 13.7%) P = .59 | 8.8% (−8.5% to 29.4%) P = .33 | 4.1% (−6.9% to 16.4%) P = .47 |
| ERT, Y/N | 0.4% (−6.0% to 7.2%) P = .90 | −1.6% (−10.5% to 8.2%) P = .74 | 2.4% (−13.1% to 20.7%) P = .77 | 0.6% (−7.4% to 9.3%) P = .88 |
| Statin, Y/N | −12.0% (−18.2% to −5.3%) P = .0007 | −24.9% (−32.3% to −16.6%) P ≤ .0001 | −4.3% (−20.2% to 14.8%) P = .63 | 5.0% (−4.0% to 14.8%) P = .28 |
| Antidiabetic medication, Y/N | −13.3% (−19.5% to −6.6%) P = .0002 | −19.2% (−27.3% to −10.2%) P ≤ .0001 | −0.8% (−16.1% to 21.2%) P = .92 | −5.7% (−13.9% to 3.4%) P = .21 |
Coefficients for repeated-measurement analysis on visit 1 to 4. Estimates are followed by 95% CI in parentheses and P values. P values less than .05 appear in bold. Age and BMI are exponential, for example, ageb while karyotype, ERT, statin, and antidiabetic medication are in percentage changes. For karyotype 45, X is reference to non-45, X. For ERT, statin, and antidiabetic medication, no treatment is reference to treatment, that is, the estimates are the effect of the specific treatment.
Abbreviations: BMI, body mass index; ERT, estrogen replacement therapy; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N, no; Y, yes.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
